The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.
Lysa
2025_Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines
Eur J Cancer 2025;220:115369
Learn more
Lysa
2025_Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials
Eur J Nucl Med Mol Imaging 2025;:
Learn more
Lysa
2025_A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
Br J Haematol 2025;:
Learn more
Lysa
2025_Interim PET after 4 Cycles Predicts Outcome in Histomolecularly Confirmed Primary Mediastinal B-Cell Lymphoma
Blood Adv 2025;:bloodadvances.2024015577
Learn more
Lysa
2025_PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction
Computerized Medical Imaging and Graphics 2025;120:102481
Learn more
Lysa
2025_Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study
Eur J Nucl Med Mol Imaging 2025;:
Learn more
Lysa
2025_Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry
Hemasphere 2025;9:e70091
Learn more
Lysa
2025_Outcome of high-grade B-cell lymphoma compared to other large B-cell lymphoma after CAR-T rescue. A DESCAR-T LYSA study
Blood Adv 2025;:bloodadvances.2024014732
Learn more
Lysa
2025_T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Nat Med 2025;:
Learn more
Lysa
2024_Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance
Blood 2024;144:2503-2516
Learn more
Lysa
2024_Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
European Journal of Cancer 2024;213:115073
Learn more
Lysa
2024_Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Blood Cancer J 2024;14:197
Learn more
Lysa
2024_Precautions to Consider in the Analysis of Prognostic and Predictive Indices
2024;65:1672-1678
Learn more
Lysa
2024_Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study
Hematol Oncol 2024;42:e3314
Learn more
Lysa
2024_Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
J Cancer Surviv 2024;:
Learn more
Lysa
2024_A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry
Adv Ther 2024;:
Learn more
Lysa
2024_Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′ RACE
Blood Adv 2024;:bloodadvances.2024013723
Learn more
Lysa
2024_Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
J Clin Oncol 2024;:JCO2400554
Learn more
Lysa
2024_MYC Rearrangement Prediction from LYSA Whole Slide Images in Large B-cell Lymphoma: A Multi-centric Validation of Self-supervised Deep Learning Models
Mod Pathol 2024;:100610
Learn more
Lysa
2024_International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
J Nucl Med 2024;65:1343-1348
Learn more
Lysa
2024_Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
Eur J Cancer 2024;208:114210
Learn more
Lysa
2024_Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with R/R B-ALL : A GRAALL study from the DESCAR-T registry
Blood Advances 2024;:bloodadvances.2024013962
Learn more
Lysa
2024_Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells
Blood Adv 2024;:bloodadvances.2024013726
Learn more
Lysa
2024_Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration
Leukemia 2024;:
Learn more